High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.

ABSTRACT:

Background

A dose-dense strategy has been considered to improve results of adjuvant chemotherapy for breast cancer. This randomised phase II trial investigated the feasibility of this approach with sequential anthracyclines and taxanes-based chemotherapy.

Methods

Patients with high-risk node-positive breast cancer were treated with three cycles of fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2), cyclophosphamide 500 mg m(-2) (FEC 100) followed by three cycles of docetaxel 100 mg m(-2) delivered at 2-weekly intervals supported by primary prophylaxis with filgrastim. All patients were randomised to either uninterrupted treatment (arm A) or to have a 2-week additional period of rest between the FEC and docetaxel (arm B). The primary endpoint was the rate of success of chemot

SUBMITTER: Brain E 

PROVIDER: S-EPMC3242527 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature